MAPT and Alzheimer disease: As shown in Table S1, we also described CSF and plasma biomarker changes in the MCI patients converting to dementia (mainly AD) versus non‐converters: as in the whole BALTAZAR MCI cohort,41 we found higher CSF tau and p‐tau181 levels; lower CSF Aβ42 levels and Aβ42/Aβ40 and Aβ42/p‐tau181 ratios, and lower plasma Aβ42/Aβ40.